What is Harrow?
Harrow, Inc. is a dedicated eyecare pharmaceutical company focused on the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products. The company's offerings span a wide range of therapeutic areas within ophthalmology, including compounded medications through its ImprimisRx division, as well as prescription products such as IHEEZO, IOPIDINE, VEVYE, ZERVIATE, MAXITROL, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, FLAREX, TRIESENCE, NATACYN, TOBRADEX ST, VERKAZIA, and FRESHKOTE. These products address critical needs from pain and inflammation management post-surgery to treating bacterial infections, fungal keratitis, and dry eye conditions, positioning Harrow as a comprehensive provider in the eyecare market.
How much funding has Harrow raised?
Harrow has raised a total of $113.5M across 2 funding rounds:
Debt
$1M
Debt
$112.5M
Debt (2020): $1M with participation from PPP
Debt (2023): $112.5M led by Oaktree Capital Management
Key Investors in Harrow
Oaktree Capital Management
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments. The company is recognized for its opportunistic, value-oriented, and risk-controlled approach to investing across credit, equity, and real estate markets. Oaktree Capital Management partners with clients worldwide to identify investment opportunities that balance potential returns with disciplined risk management.
What's next for Harrow?
The recent major strategic investment signals a new phase of growth and development for Harrow. This capital infusion is expected to accelerate the company's research and development initiatives, potentially leading to the advancement of its pipeline drugs and the expansion of its commercial footprint. Strategic partnerships and further product acquisitions may also be on the horizon as Harrow aims to solidify its position as a leader in the competitive eyecare pharmaceutical landscape. The company's focus on both novel drug development and established therapeutic solutions indicates a balanced strategy for sustained enterprise-level growth.
See full Harrow company page
